| Trial ID: | L3013 |
| Source ID: | NCT04531163
|
| Associated Drug: |
N Acetylcysteine
|
| Title: |
Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy
|
| Acronym: |
(NAC)
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetic Kidney Disease|Diabetes Mellitus, Type 2|Diabetic Nephropathies
|
| Interventions: |
DRUG: N Acetylcysteine
|
| Outcome Measures: |
Primary: Lipoprotein (a), unique lipoprotein that has emerged as an independent risk factor for developing vascular disease., 2 months|Triglycerides, Triglycerides are a type of fat (lipid) found in our blood. It is one of the lipid panel used to determine atherosclerotic risk that contributes to vascular diseases., 2 months|Systolic blood pressure, The first number of blood pressure reading and it indicates how much pressure our blood is exerting against our artery walls when the heart beats. It is a major risk factor for cardiovascular disease., 2 months |
|
| Sponsor/Collaborators: |
Sponsor: Al-Azhar University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2|PHASE3
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2019-10-01
|
| Completion Date: |
2020-12-01
|
| Results First Posted: |
|
| Last Update Posted: |
2020-08-28
|
| Locations: |
Al Azhar University, Cairo, 11651, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT04531163
|
